Skip to main content
PLOS One logoLink to PLOS One
. 2024 Oct 24;19(10):e0308865. doi: 10.1371/journal.pone.0308865

‘Age specific variations in ovarian reserves in healthy fertile and infertile women: A cross sectional study

Neena Malhotra 1,*, Pankush Gupta 2, Saloni Kamboj 1, Pradeep Chaturvedi 3, Rintu Kutum 4
Editor: Natasha L Pritchard5
PMCID: PMC11500972  PMID: 39446778

Abstract

Ovarian reserve tests are valuable for evaluation of female fertility, and to formulate appropriate treatment strategies for infertile women. Antral follicle count (AFC) and Anti-Mullerian hormone (AMH) are most reliable markers of ovarian reserve which are related inversely to age. There are many factors that affect ovarian reserve like race, ethnicity, fertility status, BMI or any chronic illness. We conducted this study to find outage specific nomograms for AMH and AFC among fertile and Infertile Indian women, to find out any variations between fertile and Infertile ovarian reserves at various centiles, to define the age cut-off of decline in AMH and AFC among fertile and Infertile Indian women and to find correlation between AMH and AFC. It was a prospective cross sectional single centre study conducted at a tertiary hospital of northern India from March 2017 to February 2022. Fertile healthy women were recruited from family planning clinic, oocyte donors and subfertile women from Gynaecology and ART clinic. AMH was done using ELISA, Beckmann Coulter Gen II assay and AFC was done using TVS with high frequency probe (9.0 MHZ, Voluson,S-6, GE Healthcare, USA) by trained personnel. R Statistical Programming Language was used for statistical modelling and visualization. Age-specific AFC centile chart and AMH centile chart were generated using GAMLSS (Generalized Additive Models for Location Scale and Shape) package available in R Statistical Computing Language. A Non-linear decline in ovarian reserves among fertile, while linear among infertile women was seen. Centiles defined for both groups with a faster decline in infertile women. Age cut off for decline in AMH and AFC in fertile women approximately 31 years using ROC analysis and Age cut off for decline in AMH and AFC in infertile women is approximately 34 years. There seems to be a good correlation between AFC and AMH. We need to counsel women to consider child bearing well before ovarian reserves decline (31–34 years).

Introduction

Use of ART techniques have been on a rise with increase in infertility [1]. Over recent years, testing of ovarian reserve to predict future reproductive life has become crucial while women postpone childbearing globally [2]. Testing for ovarian reserve is fundamental in planning the course of infertility treatment and offering ART to those with borderline reserves besides predicting outcomes of treatment [3]. There are varieties of ovarian reserve tests that include ultrasound and biochemical parameters [3]. Antral follicle count (AFC) and anti-Mullerian hormone (AMH) have been shown to be the best markers of ovarian reserve [4, 5].

Anti-Mullerian hormone (AMH) is a dimeric glycoprotein which is a member of the transforming growth factor beta (TGF-b) superfamily, produced by granulosa cells of primordial follicles that have undergone initial recruitment, and is thought to reflect the size and quality of the ovarian reserve [6]. In addition, AMH inhibits follicular sensitivity to follicle stimulating hormone (FSH) and plays a role in the process of follicle selection and dominance. Currently, AMH is considered as an optimal biomarker that reflects ovarian reserve, convenient in detection and more effective than other biomarkers, including FSH and estradiol (E2). Measuring AMH during an initial fertility workup is crucial to plan ART cycles, including protocols, dosing of gonadotropins and also predicting the response to ovarian stimulation. These results can be used to determine the recombinant human FSH starting dose and predict the final oocyte yields and develop a nomogram that could predict oocyte yield. Lee et al. investigated the cutoff level of serum AMH for predicting poor (number of oocytes retrieved, ≤3), normal (4–19), and high responders (≥20). Especially for predicting poor responders, the cutoff level was 1.08 ng/mL, with 85.8% sensitivity and 78.6% sensitivity [7]. In a multicentric trial by Nelson et al, Anti-mullerian hormone proved to be a stronger predictor of ovarian response to gonadotropin therapy compared to AFC utilizing GnRH agonist and GnRH antagonist protocols. Antral follicle count provided no added predictive value beyond AMH [8]. AMH has also found usefulness in even predicting rate of euploid blastocyst besides live birth, after In-vitro fertilization/ intracytoplasmic cycles [9]. Further beyond infertility it is utilized by clinicians to assess the ovarian reserve and predict menopause age [10]. Therefore, the reference range of AMH in normal healthy women is needed to provide useful information on ovarian function that can be of potential clinical benefit. Anti-Mullerian hormone is measured using enzyme linked immunosorbent assays (ELISAs). Various assays are available: Gen II (Beckman Coulter); pico AMH (Ansh Labs); and Elecsys (Roche) [11]. Previous studies have mostly measured AMH levels using ELISAs, the Diagnostics Systems Laboratory (DSL 10–14400) assay or the Immunotech (IOT, A11893 IVD, EU) assay [12]. These assays utilize different primary antibodies against AMH and different standards, and consequently, the crude values reported differed substantially. With the consolidation of these 2 companies by Beckman Coulter in 2011, as sole ownership of the patent to measure mammalian AMH, there is finally a single commercially available assay: the AMH Gen II assay (A79765), which has fully replaced the DSL and IOT assays [13]. Therefore, using the Beckman Coulter Gen II assay to estimate the reference range for AMH is more practical. However, only a few studies established the reference range for AMH using the new Gen II assay, especially for Indian women [14].

Antral follicle count (AFC) also serves as an objective ovarian reserve test helping decide treatment protocols and anticipating response. AFC is the most commonly used ultrasound marker to identify ovarian reserve and is reliable and easy to measure [15]. It consists of counting of all follicles in the range of 2–10 mm visualized through high resolution transvaginal ultrasound examination. Assessment of AFC has been a simple method of predicting the occurrence of menopause and thus the duration of the reproductive lifespan [16]. It is well established that the female reproductive function deteriorates with age because of reduction of the ovarian follicle pool [17]. Several studies of autopsy and surgical specimens showed that the number of antral follicles is related to the number of primordial follicles within the ovaries [18]. In particular, the number of small antral follicles decreases with age similarly to the number of primordial follicles [17, 19]. Indeed, several studies have demonstrated that AFC declines with chronologic age in women, although it is still not clear whether this decline has a biphasic [20] or a linear pattern [21, 22].

Ovarian reserve markers including AMH and AFC are prone to variations because of race, ethnicity, use of hormones including oral contraceptives [23]. Various studies have been published on nomograms based on AMH and AFC for fertile and infertile population [24, 25]. As the values are affected by race, ethnicity, it becomes prudent for each population to have a nomogram to be used as reference. Several AMH–age nomograms have been reported before; however, most of the studies used hospital inpatient samples, particularly samples from infertile women instead of healthy females. With improved access to ART services, more and more Indian women are seeking treatment and using American or European standards may not seem justifiable. There is also evidence that ovarian reserves among Indian women decline earlier compared to women from Europe [3, 26, 27]. However, this data comes from women who had undergone ART cycle and may not reflect the nomograms as would come from women other that the infertile cohort. The reference range for AMH levels obtained from a large, population-based sample of healthy women was believed to be more practical, reliable, and accurate in representing the normal population, therefore, additional studies were warranted to determine that.

Currently there are no age-related centile charts for AFC and AMH from Indian women. The present study was aimed to derive nomograms for AMH and AFC among fertile and infertile women of Indian origin, indicating the trends in decline and the relationship between two ovarian reserve markers. Additionally, we evaluated the relationship of AMH and AFC with age to provide an optimal model of decline in AMH and AFC with age.

Materials and methods

In a cross-sectional study, conducted at a tertiary referral hospital in North India, both infertile and healthy fertile women who had borne one child conceived spontaneously were invited for testing ovarian reserves at one time. The study was approved by the ethics committee of the Institute (IEC-491/07.10.2016) and all participants gave informed written consents to be part of the study. The study was conducted from January 2017 until December 2022, with recruitment affected by the COVID pandemic, enrolling 3240 women; 1902 infertile and 1338 healthy women as controls. The participating women including infertile cohort attended fertility and ART clinics while fertile cohort consisted of those attending the family planning and contraception clinics or healthy oocyte donors with confirmed fertility.

The inclusion criteria for infertile women were age 21–40 years, with infertility of more than one year, while healthy age and BMI matched women were selected as controls. Women with conditions that could affect ovarian reserves including endometriosis, PCOS, previous ovarian surgery, immunological disorders and those on gonadotoxic therapy were excluded from both cohorts. Also, women with co-morbidities such as diabetes mellitus, morbid obesity were excluded. Informed consent was obtained from all women in both the cohorts, informing them that these tests will be confidential and not relevant on future child bearing especially in the fertile cohort.

Testing for both biomarkers of ovarian reserve was done early in the follicular phase between day 2 to day 6 of menstrual cycle ensuring no intake of oral contraceptive pills prior to testing in either group. Blood samples for AMH were centrifuged after collection were aliquoted and stored at -80 degrees for future use within 4 weeks of blood collection. Serum Anti Mullerian Hormone was measured in all samples using the Beckman Coulter (M/S Immunotech) AMH Gen II ELISA kits. This kit uses the two-site ‘sandwich’ assay and has an analytical sensitivity of 0.08ng/ml. This method has got a validated correlation with the automated access AMH assay [28] The limit of detection for Gen II was 0.18 nmg/ml and the measurement range varied between 0.16 to 22.6 ngm/ml.

Antral follicle counts were done using high frequency transvaginal transducer (8.5 MHz; S-6, GE 3600 Healthcare, USA)when follicles between 2–8 mm were measures in three planes in each ovary, number totaled for both ovaries All scans were done the same personnel (NM, PG) who were trained sufficiently to ensure consistency. All data recorded on the proforma was entered in EXCEL and further statistical analysis was conducted using R software environment.

Statistical analysis

Baseline characteristics such as age, BMI, AFC, AMH were measure for both the fertile as well as infertile cohorts, which were expressed as mean and standard deviations, percentages whichever was most appropriate. Both cohorts were divided into six sub groups based on age.

Age specific centile charts for AMH and AFC were generated as per the CG-LMS method using GAMLSS (Generalized Additive Models for Location Scale and Shape) package available in R Statistical Computing Language. This method produces a model that specifies the centiles in terms of age-specific curves called L (skewness), M (median) and S (coefficient of variation). At each age point, M curve corresponds to the median AFC/AMH level, S curve corresponds to the coefficient of variation and L curve allows for age dependent skewness of distribution of AMH/AFC. The value of any centile at a given age can be computed from the values of L,M and S. Six empirical centiles, including the 3rd, 10th, 25th, 50th, 75th and 90th centiles, and nomogram tables were constructed. Receiver Operator Characteristic(ROC) curve analysis was conducted to analyze the predictive accuracy of age with respect of AFC and AMH and to determine the cut-off values using the Area Under the Curve (AUC) analysis. The cut off values for AMH of <1.2 ngm/ml and AFC of < 5 was taken as per the POSEDION criteria in describing diminished ovarian reserves while generating the ROC [29].

Results

Table 1 presents the baseline values of age, BMI, AMH and AFC values in the fertile and infertile groups.

Table 1. Baseline parameters of fertile and infertile subjects.

Parameter Infertile Fertile
Number 1902 1338
Age* (Years±SD) 31.1± 4.78 28.7±5.07
Infertility
Primary, n (%) 1486(78.2%) -
Secondary, n (%) 416(21.8%) -
BMI* (Kg/m2±SD) 25.09±4.43 24.23± 2.23
AMH* (ng/dl±SD) 3.4± 2.48 4.37±2.62
AFC*(n±SD) 12±6.8 15±6.2

*- Mean, BMI- Body Mass Index, AMH- Antimullerian Hormone, AFC- Antral Follicle count

Age segregated number were comparable in the fertile and infertile groups across different sub groups, with lower number of women between ages 40 and beyond (Table 1 and Fig 1).

Fig 1. Age segregated subgroup analysis of subjects.

Fig 1

Tables 2 and 3 provides the age segregated subgroup analysis of AMH and AFC (Nomograms). The mean AMH and AFC values were higher in the fertile group compared to the infertile with the differences being significant in the age group of 20–25 and 25–30 years sub-groups.

Table 2. Nomograms for AMH using LMS model.

Age 3-ctrl 3-case 10-ctrl 10-case 25-ctrl 25-case 50-ctrl 50-case 75-ctrl 75-case 90-ctrl 90-case 95-ctrl 95-case
20 2.22 0.83 3.25 1.91 4.37 3.28 5.7 5.01 7.1 6.89 8.41 8.67 9.22 9.77
21 1.93 0.73 3 1.75 4.18 3.09 5.59 4.8 7.08 6.65 8.49 8.42 9.35 9.51
22 1.65 0.63 2.74 1.6 3.98 2.9 5.46 4.59 7.04 6.43 8.54 8.19 9.47 9.28
23 1.37 0.54 2.47 1.44 3.75 2.71 5.31 4.38 6.98 6.22 8.56 7.99 9.55 9.09
24 1.11 0.45 2.2 1.28 3.52 2.52 5.13 4.18 6.89 6.04 8.55 7.82 9.59 8.94
25 0.88 0.38 1.94 1.14 3.27 2.34 4.94 3.99 6.77 5.86 8.51 7.67 9.6 8.8
26 0.7 0.31 1.69 1.01 3.02 2.17 4.73 3.81 6.62 5.69 8.43 7.52 9.56 8.67
27 0.55 0.27 1.47 0.9 2.77 2.01 4.5 3.63 6.44 5.52 8.31 7.38 9.48 8.55
28 0.43 0.23 1.26 0.8 2.53 1.86 4.27 3.47 6.23 5.37 8.15 7.25 9.35 8.43
29 0.34 0.2 1.09 0.71 2.3 1.73 4.02 3.31 5.99 5.23 7.94 7.13 9.16 8.34
30 0.27 0.17 0.93 0.64 2.08 1.6 3.76 3.17 5.72 5.09 7.67 7.01 8.9 8.24
31 0.22 0.15 0.8 0.58 1.86 1.49 3.49 3.02 5.42 4.93 7.35 6.87 8.58 8.1
32 0.18 0.13 0.68 0.52 1.67 1.39 3.22 2.87 5.11 4.75 7.01 6.68 8.22 7.91
33 0.15 0.12 0.59 0.48 1.5 1.28 2.99 2.72 4.82 4.56 6.69 6.47 7.88 7.69
34 0.13 0.11 0.52 0.43 1.37 1.19 2.79 2.57 4.59 4.38 6.42 6.26 7.6 7.47
35 0.11 0.09 0.47 0.39 1.26 1.1 2.64 2.43 4.4 4.21 6.22 6.07 7.4 7.27
36 0.1 0.09 0.42 0.36 1.17 1.02 2.5 2.3 4.24 4.04 6.05 5.88 7.22 7.08
37 0.09 0.08 0.39 0.33 1.09 0.95 2.37 2.18 4.08 3.88 5.86 5.7 7.03 6.89
38 0.08 0.07 0.35 0.3 1 0.88 2.23 2.04 3.88 3.69 5.63 5.47 6.77 6.65
39 0.07 0.06 0.31 0.26 0.92 0.79 2.07 1.86 3.64 3.41 5.31 5.1 6.41 6.22
40 0.06 0.05 0.28 0.22 0.82 0.65 1.87 1.57 3.33 2.9 4.89 4.36 5.92 5.34

Table 3. Nomograms for AFC using LMS model.

Age 3-ctrl 3-case 10-ctrl 10-case 25-ctrl 25-case 50-ctrl 50-case 75-ctrl 75-case 90-ctrl 90-case 95-ctrl 95-case
20 6.9 5.56 11.13 8.47 14.59 11.88 17.73 16.22 20.77 21.2 24.02 26.31 26.52 29.7
21 7.12 5.23 11.22 8.09 14.5 11.47 17.44 15.8 20.3 20.77 23.35 25.88 25.7 29.28
22 7.26 4.9 11.24 7.72 14.36 11.07 17.16 15.37 19.86 20.33 22.75 25.45 24.98 28.86
23 7.21 4.59 11.11 7.35 14.15 10.66 16.87 14.94 19.5 19.89 22.31 25.01 24.48 28.42
24 6.87 4.28 10.75 6.99 13.83 10.26 16.59 14.51 19.27 19.44 22.13 24.56 24.33 27.98
25 6.28 3.98 10.19 6.64 13.41 9.87 16.34 14.08 19.18 19 22.22 24.1 24.55 27.52
26 5.64 3.7 9.56 6.3 12.97 9.48 16.13 13.65 19.21 18.54 22.49 23.64 25.01 27.05
27 5.11 3.42 9 5.96 12.55 9.09 15.9 13.23 19.17 18.09 22.67 23.16 25.35 26.57
28 4.73 3.16 8.53 5.63 12.1 8.71 15.53 12.8 18.89 17.62 22.49 22.68 25.24 26.08
29 4.39 2.9 8.04 5.31 11.57 8.33 14.98 12.37 18.35 17.16 21.94 22.19 24.69 25.57
30 3.96 2.66 7.43 4.99 10.88 7.96 14.27 11.94 17.64 16.68 21.24 21.68 24 25.05
31 3.44 2.43 6.66 4.69 10.04 7.59 13.47 11.51 16.9 16.21 20.58 21.17 23.39 24.52
32 2.9 2.21 5.84 4.39 9.15 7.23 12.65 11.09 16.21 15.72 20.04 20.64 22.97 23.97
33 2.42 2.01 5.06 4.1 8.27 6.87 11.85 10.66 15.58 15.24 19.62 20.1 22.7 23.4
34 2.04 1.81 4.4 3.83 7.49 6.52 11.13 10.23 15.04 14.74 19.3 19.55 22.56 22.81
35 1.75 1.63 3.87 3.56 6.82 6.17 10.51 9.81 14.6 14.24 19.11 18.98 22.56 22.21
36 1.53 1.46 3.47 3.3 6.28 5.83 9.98 9.38 14.2 13.73 18.93 18.4 22.55 21.58
37 1.37 1.3 3.13 3.05 5.79 5.49 9.42 8.96 13.69 13.22 18.52 17.81 22.25 20.94
38 1.22 1.16 2.81 2.81 5.28 5.17 8.76 8.53 12.94 12.7 17.73 17.2 21.42 20.27
39 1.05 1.02 2.44 2.58 4.63 4.84 7.78 8.1 11.64 12.17 16.09 16.57 19.54 19.58
40 0.81 0.9 1.89 2.36 3.62 4.53 6.14 7.68 9.27 11.63 12.91 15.92 15.73 18.87

The centiles of AMH and AFC were computed at each age point using the linear specification of the CG-LMS method (Figs 2 and 3).

Fig 2. Centiles of AMH computed at each age point (fertile population).

Fig 2

Fig 3. Centiles of AMH computed at each age point (Infertile population).

Fig 3

Age-related nomograms for AMH and AFC respectively were generated. Decline in AMH and AFC was linear in the infertile cohort while the fertile cohort had a non-linear pattern in decline. The rate of decline OF AMH was found to be 0.192 (± 0.05) in fertile group and 0.172(± 0.04) in the infertile group. The rate of decline of AFC was found to be 0.65 (± 0.41) in fertile group and 0.56(± 0.05) in the infertile group. The estimated centiles for AMH and AFC for the fertile and infertile groups were generated (Figs 4A, 4B, 5A and 5B).

Fig 4.

Fig 4

(a) Centiles of AFC computed at each age point (Fertile population). (b) Centiles of AFC computed at each age point (Infertile population).

Fig 5.

Fig 5

(a) The estimated centiles for AMH for the fertile and infertile groups. (b) The estimated centiles for AFC for the fertile and infertile groups.

CG-LMS method using more complex models did not result in a significant improvement in the data-fit. Age cut off for decline in AMH and AFC in fertile women came out to be approximately 31 years using ROC analysis. Age cut off for decline in AMH and AFC in infertile women was found approximately 34 years. (Figs 69).

Fig 6. Age cut off for decline in AMH in fertile women.

Fig 6

Fig 9. Age cut off for decline in AFC in infertile women.

Fig 9

Fig 7. Age cut off for decline in AMH in infertile women.

Fig 7

Fig 8. Age cut off for decline in AFC in fertile women.

Fig 8

The correlation between AMH and AFC was estimated for both infertile and fertile populations and it was found that both the parameters were significantly correlated (Fig 10)

Fig 10. Correlation between AMH and AFC for both infertile and fertile populations.

Fig 10

Discussion

The present study is the first of its kind to develop nomograms of Antimullerian Hormone and Antral follicle count for both fertile and infertile women of Indian origin. AMH and AFC are the two most frequently used ovarian reserve markers to prognosticate infertile couples regarding future fertility prospects. Our study with a large sample size showed the mean values of AMH to be significantly lower in infertile than fertile populations. As the patients with endometriosis, tuberculosis and PCOS were excluded, this difference in AMH values in corresponding age groups throws light on the possibility of certain ovarian factors at play causing decreased reserve in the infertile compared to age and BMI matched fertile women The difference in mean AMH values among infertile and fertile was seen across all centiles. Previously various authors have published nomograms and have shown similar age-related decline in AMH values [24, 25, 30]. Most studies showed a peak in AMH levels at 25 years with a further decline in the values. No such peak was seen in women from our study among the infertile group, though the fertile women showed a peak at higher centiles. This could be attributed to an ovarian insult at an early age, especially in the infertile group from a non-disease ovary, responsible for declining reserves. The age-related decline in AMH across all centiles was seen in a linear fashion in our study. However, studies by Nelson et al. (2011) and Seifer et al. (2011) among infertile Caucasian women showed that AMH declined in a non-linear pattern with age, which was best described by aquadratic equation; while the most recent study by Naasan et al. (2015) found that AMH declined in a linear biphasic fashion with age [31]. Nomograms for AFC were also computed for the infertile and fertile groups. The mean AFC was significantly higher in controls than cases across centiles though the difference diminished across higher centiles. A study by Iglesias et al where AMH and AFC were measured for the Indian and Spanish populations showed advancement in ovarian age in the Indian population compared to the Spanish population [27]. Our results contradict these findings as even the infertile population ovarian reserve markers were higher in our study than previously quoted. The findings of Olcha et al who studied the ancestry informative markers population’ suggest that after controlling for age and BMI, AMH levels are not different based upon these genetic markers of ethnicity [32]. The age cut-off for decline in AMH (< 1.2 ngm/ml)was 31.2 and 33.2 years among the fertile and infertile women respectively, while it was 34.4 and 31.7 years among fertile and infertile women respectively for AFC (< 5). The cutoff was developed taking the POESIDON criteria to define diminished ovarian reserves [29]. This highlighted that women tend to decline ovarian reserves between 31.2 to 34.4 years given the above cut-off values for defining diminished ovarian reserves. This data may be useful in counseling women on birth planning, considering the trends on postponement in child bearing among Indian women for career pursuits.

There was positive correlation between AMH and AFC in our study. A study by Zhang et al demonstrated that one in five patients show discordance in AMH and AFC with AFC being better than AMH for DOR prediction [33]. As AFC reflect the recruited follicle and AMH an ovarian reserve marker, AMH prognosticates the overall fertility potential further necessitating the need for nomograms.

When considering PCOS patients, stratifying patients based on AMH values can predict IVF outcomes in patients as shown by Reshef Tal et al where women with low AMHhad higher LBR compared to high AMH with PCOS [34]. The cut-off values to label a patient as PCOS depending on AMH has not been defined. The values >95th centiles of these nomograms can serve as an indicator to anticipate PCOS and plan further ART treatment. In a study conducted on chinese ethnic group in Singapore revealed that AFC and AMH generally decline in a linear fashion with increasing age, although there is a slight non-linear pattern observed for AMH in the 90th and 97th percentiles. These data showed that the ovarian reserve for older patients decreases at a constant rate over time. Faster decline rates of AFC and AMH were observed in higher centiles [30]

The strength of this study is the large sample size coming from a single center avoiding variations in the methods used to assess both the ovarian reserve markers, besides inclusion of adequate number of women from each age group. Further the assay used was Gen 2 ELISA, and all AFC measurements had little inter-observer variations. While the recent methods to assess AMH include automated assays, our study was initiated well before these assays were readily available in India. However, the difference between the ELISA Gen 2 and the automated assays can be computed from available studies and an always be factored while using these nomograms as reference by the clinicians.

The study had its limitation in particular, conducted on women from Northern India and variations among women hailing from other regions are anticipated given the large country with racial diversity. Further we did not have the outcomes from treatment cycles including ovarian stimulation with or without intra-uterine insemination and IVF, from the infertile cohort in terms of time to pregnancy, clinical pregnancy, live birth, eggs retrieved, fertilized and good quality embryos obtained and cryopreserved.

Conclusion

The study provides nomograms to be used as reference levels for Indian females while assessing their ovarian reserve markers and reduce time to pregnancy by formulating an individualized plan. It gives insight on the age at which North Indian women suggest declining fertility and may be useful to advise on options available while women plan to defer child-bearing.

Supporting information

S1 Rawdata

(XLSX)

pone.0308865.s001.xlsx (99.1KB, xlsx)

Data Availability

ll relevant data are within the manuscript and its Supporting Information files.

Funding Statement

WHO is providing funding for publication assistance. REC-PDCL provided funds for study through CSR initiative.

References

  • 1.Sunderam S., Kissin D. M., Zhang Y., Folger S. G., Boulet S. L., Warner L., et al. (2019). Assisted Reproductive Technology Surveillance—United States, 2016. MMWR Surveill. Summ. 68, 1–23. doi: 10.15585/mmwr.ss6804a1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Maheshwari Abha, Fowler Paul, Bhattacharya Siladitya, Assessment of ovarian reserve—should we perform tests of ovarian reserve routinely?, Human Reproduction, Volume 21, Issue 11, 1 November 2006, Pages 2729–2735, doi: 10.1093/humrep/del188 [DOI] [PubMed] [Google Scholar]
  • 3.Jirge PR. Ovarian reserve tests. J Hum Reprod Sci. 2011. Sep;4(3):108–13. doi: 10.4103/0974-1208.92283 ; PMCID: PMC3276943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Penzias Alan, Azziz Ricardo, Bendikson Kristin, et al. Testing and interpreting measures of ovarian reserve: a committee opinion, Fertility and Sterility, Volume 114, Issue 6,2020, Pages 1151–1157, ISSN 0015-0282, doi: 10.1016/j.fertnstert.2020.09.134 [DOI] [PubMed] [Google Scholar]
  • 5.Khan H.L., Bhatti S., Suhail S. et al. Antral follicle count (AFC) and serum anti-Müllerian hormone (AMH) are the predictors of natural fecundability have similar trends irrespective of fertility status and menstrual characteristics among fertile and infertile women below the age of 40 years. ReprodBiolEndocrinol 17, 20 (2019). 10.1186/s12958-019-0464-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Josso N, di Clemente N, Gouédard L. Anti-Müllerian hormone and its receptors. Mol Cell Endocrinol. 2001;179:25–32. [DOI] [PubMed] [Google Scholar]
  • 7.Lee, Jae Eun & Lee, Jung Ryeol& Jee, Byung& Suh, Chang & Kim, Ki & Lee, Won, et al. (2012). Clinical application of anti-Müllerian hormone as a predictor of controlled ovarian hyperstimulation outcome. Clinical and experimental reproductive medicine. 39. 176–81. doi: 10.5653/cerm.2012.39.4.176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Nelson SM, Klein BM, Arce JC. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. FertilSteril. 2015. Apr;103(4):923–930.e1. doi: 10.1016/j.fertnstert.2014.12.114 Epub 2015 Jan 24. . [DOI] [PubMed] [Google Scholar]
  • 9.La Marca A, Minasi MG, Sighinolfi G, Greco P, Argento C, Grisendi V, et al. Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles. FertilSteril. 2017. Nov;108(5):777–783.e2. doi: 10.1016/j.fertnstert [DOI] [PubMed] [Google Scholar]
  • 10.Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. Maturitas. 2009. Aug 20;63(4):280–91. doi: 10.1016/j.maturitas.2009.06.007 Epub 2009 Jul 23. . [DOI] [PubMed] [Google Scholar]
  • 11.Loes M E Moolhuijsen, Yvonne V Louwers, Joop S E Laven, Jenny A Visser, Comparison of 3 Different AMH Assays With AMH Levels and Follicle Count in Women With Polycystic Ovary Syndrome, The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 9, September 2022, Pages e3714–e3722, 10.1210/clinem/dgac370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Nelson SM, Yates RW, Lyall H, et al. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867–75. [DOI] [PubMed] [Google Scholar]
  • 13.Wallace AM, Faye SA, Fleming R, Nelson SM. A multicenter evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II). Ann ClinBiochem 2011;48:370–373. [DOI] [PubMed] [Google Scholar]
  • 14.Gunasheela D, Murali R, Appaneravanda LC, Gerstl B, Kumar A, Sengeetha N, et al. Age-Specific Distribution of Serum Anti-Mullerian Hormone and Antral Follicle Count in Indian Infertile Women. J Hum Reprod Sci. 2021. Oct-Dec;14(4):372–379. doi: 10.4103/jhrs.jhrs_65_21 Epub 2021 Dec 31. ; PMCID: PMC8812401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Broekmans FJ, de Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. FertilSteril 2009. [Epub ahead of print] doi: 10.1016/j.fertnstert.2009.04.040 [DOI] [PubMed] [Google Scholar]
  • 16.Faddy M.J., Gosden R.G., Gougeon A., Richardson S.J., J.F. Nelson Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. HumReprod, 7 (1992), pp. 1342–1346. [DOI] [PubMed] [Google Scholar]
  • 17.Block E. Quantitative morphological investigations of the follicular system in women; variations at different ages Acta Anat (Basel), 14 (1952), pp. 108–123. [DOI] [PubMed] [Google Scholar]
  • 18.Faddy M.J., Gosden R.G., Gougeon A., Richardson S.J., Nelson J.F. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. HumReprod, 7 (1992), pp. 1342–1346. doi: 10.1093/oxfordjournals.humrep.a137570 [DOI] [PubMed] [Google Scholar]
  • 19.Ng EH, Yeung W.S, Fong D.Y, Ho P.C. Effects of age on hormonal and ultrasound markers of ovarian reserve in Chinese women with proven fertility. HumReprod, 18 (2003), pp. 2169–2174. doi: 10.1093/humrep/deg404 [DOI] [PubMed] [Google Scholar]
  • 20.Scheffer G.J., Broekmans F.J., Dorland M., Habbema J.D., Looman C.W., teVelde E.R. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. FertilSteril, 72 (1999), pp. 845–851. doi: 10.1016/s0015-0282(99)00396-9 [DOI] [PubMed] [Google Scholar]
  • 21.Ng EH, Yeung W.S, Fong D.Y, Ho P.C. Effects of age on hormonal and ultrasound markers of ovarian reserve in Chinese women with proven fertility. HumReprod, 18 (2003), pp. 2169–2174 doi: 10.1093/humrep/deg404 [DOI] [PubMed] [Google Scholar]
  • 22.Rosen MP, Sternfeld B, Schuh-Huerta SM, ReijoPera RA, McCulloch CE, Cedars MI Antral follicle count: absence of significant midlife decline. FertilSteril 2010. doi: 10.1016/j.fertnstert.2009.12.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Patel AP, Patel JA, Cruz M, Gupte-Shah A, Garcia Velasco JA, Banker MR. Ethnicity is an independent predictor of IVF-ICSI outcome: a study of 5,549 cycles in Spain and India. GynecolEndocrinol. 2016. Oct;32(10):819–822. doi: 10.1080/09513590.2016.1188377 Epub 2016 May 31. . [DOI] [PubMed] [Google Scholar]
  • 24.Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. FertilSteril. 2011. Feb;95(2):736–41.e1-3. doi: 10.1016/j.fertnstert.2010.08.022 Epub 2010 Sep 24. . [DOI] [PubMed] [Google Scholar]
  • 25.Lie Fong S., Visser J. A., Welt C. K., de Rijke Y. B., Eijkemans M. J. C., Broekmans F. J., et al. , Serum Anti-Müllerian Hormone Levels in Healthy Females: A Nomogram Ranging from Infancy to Adulthood, The Journal of Clinical Endocrinology & Metabolism, Volume 97, Issue 12, 1 December 2012, Pages 4650–4655, 10.1210/jc.2012-1440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts DH, et al. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. FertilSteril. 2009. Nov;92(5):1674–8. doi: 10.1016/j.fertnstert.2008.08.110 Epub 2008 Oct 18. ; PMCID: PMC3037722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Iglesias C, Banker M, Mahajan N, Herrero L, Meseguer M, Garcia-Velasco JA. Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women. FertilSteril. 2014. Jul;102(1):244–9. doi: 10.1016/j.fertnstert.2014.03.050 Epub 2014 Apr 29. . [DOI] [PubMed] [Google Scholar]
  • 28.Punchoo R, Bhoora S. Variation in the Measurement of Anti-Müllerian Hormone—What Are the Laboratory Issues? Front Endocrinol (Lausanne). 2021. Sep 3;12:719029. doi: 10.3389/fendo.2021.719029 ; PMCID: PMC8446602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number),.Alviggi C, Andersen CY, et al.: A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. FertilSteril. 2016;105(6):1452–3. doi: 10.1016/j.fertnstert.2016.02.005 [DOI] [PubMed] [Google Scholar]
  • 30.Loy SL, Cheung YB, Fortier MV, Ong CL, Tan HH, Nadarajah S, et al. Age-related nomograms for antral follicle count and anti-Mullerian hormone for subfertile Chinese women in Singapore. PLoS One. 2017. Dec 14;12(12):e0189830. doi: 10.1371/journal.pone.0189830 ; PMCID: PMC5730199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Naasan MN, Harrity C, Pentony L, Mocanu E. Anti-Mullerian hormone normogram in an Irish subfertile population. Ir J Med Sci. 2015. Mar;184(1):213–8. doi: 10.1007/s11845-014-1089-0 Epub 2014 Feb 23. . [DOI] [PubMed] [Google Scholar]
  • 32.Olcha M, Franasiak JM, Shastri S, Molinaro TA, Congdon H, Treff NR, et al. Genotypically determined ancestry across an infertile population: ovarian reserve and response parameters are not influenced by continental origin. FertilSteril. 2016. Aug;106(2):475–80. doi: 10.1016/j.fertnstert.2016.03.052 Epub 2016 Apr 14. . [DOI] [PubMed] [Google Scholar]
  • 33.Zhang Y, Xu Y, Xue Q, Shang J, Yang X, Shan X, et al. Discordance between antral follicle counts and anti-Müllerian hormone levels in women undergoing in vitro fertilization. ReprodBiolEndocrinol. 2019. Jul 4;17(1):51. doi: 10.1186/s12958-019-0497-4 ; PMCID: PMC6610959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Tal R, Seifer CM, Khanimov M, Seifer DB, Tal O. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. ReprodBiolEndocrinol. 2020. Mar 10;18(1):20. doi: 10.1186/s12958-020-00581-4 ; PMCID: PMC7065318. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Vehbi Yavuz Tokgöz

1 Apr 2024

PONE-D-23-38873Age specific variations in ovarian reserves in healthy fertile and infertile women: A cross sectional studyPLOS ONE

Dear Dr. malhotra,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================The current manuscript may provide important information to the literature. After completion the required corrections of the reviewers, we will review again and make our final decision.  ==============================

Please submit your revised manuscript by May 16 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Vehbi Yavuz Tokgöz, M. D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

3. Please amend your manuscript to include your abstract after the title page.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a cross sectional study and provide us nomograms for AMH and AFC among fertile and infertile women of Indian origin, indicating the trends in decline and the relationship between two ovarian reserve markers. The present study aims to derive nomograms for AMH and AFC among fertile and infertile women of Indian origin, indicating the trends in decline and the relationship between two ovarian reserve markers. The researchers included 1902 infertile and 1338 healthy women for controls. This is a cross sectional study and has a good sample size.

The following points should be corrected and clarified:

- The authors should change the sentence 'Assessment of AFC has been a simple method of predicting the occurrence of menopause and thus the duration of the reproductive lifespan'. Because we know, based on the work of Kim C. et al. ‘Among women aged 45-49 years, undetectable AMH concentrations were associated with a greater than 60% probability of menopause within 5 years, whereas approximately 1/3 of women with no or just one antral follicle experienced menopause within 5 years. Both low and high concentrations of FSH were associated with greater odds of menopause than intermediate concentrations. Models with multiple markers did not improve the prediction of menopause over that afforded by models with single markers’. (Maturitas 2017 Aug:102:18-25).

- In the infertile population, were couples with infertility due to male factor and tubal factor excluded?

- The p value acronyms in the figures should always be arranged in the same format

- Explanations on figures and tables should be clearer

- Spelling and typographical errors in the article should be corrected

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Oct 24;19(10):e0308865. doi: 10.1371/journal.pone.0308865.r002

Author response to Decision Letter 0


5 May 2024

RESPONSE TO EDITORS

1. Formatting done as per Journal protocol

2. Raw Data Attached

3. Abstract included after Title page

4. Corrected Reference list attached

RESPONSE TO REVIEWERS

The authors should change the sentence 'Assessment of AFC has been a simple method of predicting the occurrence of menopause and thus the duration of the reproductive lifespan'. Because we know, based on the work of Kim C. et al. ‘Among women aged 45-49 years, undetectable AMH concentrations were associated with a greater than 60% probability of menopause within 5 years, whereas approximately 1/3 of women with no or just one antral follicle experienced menopause within 5 years. Both low and high concentrations of FSH were associated with greater odds of menopause than intermediate concentrations. Models with multiple markers did not improve the prediction of menopause over that afforded by models with single markers’. (Maturitas 2017 Aug:102:18-25).

ANSWER : editing done ( AMH and FSH also added for predicting menopause ).

- In the infertile population, were couples with infertility due to male factor and tubal factor excluded?

ANSWER : Severe Male factor infertility were excluded but mild male factor were included. Tubal factor infertility were all included.

- The p value acronyms in the figures should always be arranged in the same format

Answer : Changed as per requirements

- Explanations on figures and tables should be clearer

Answer : Captions added.

- Spelling and typographical errors in the article should be corrected

Answer : Corrections done.

Attachment

Submitted filename: RESPONSE TO EDITORS & REVIEWERS.docx

pone.0308865.s002.docx (15.8KB, docx)

Decision Letter 1

Natasha L Pritchard

1 Aug 2024

Age specific variations in ovarian reserves in healthy fertile and infertile women: A cross sectional study

PONE-D-23-38873R1

Dear Dr. Nenna Malhotra

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Natasha L Pritchard

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Dear author

Your responses are appropriate. I think that it should be clearly stated that tubal factor/ mild male factor infertility is included in the infertile group. This would only bias your results towards the null hypothesis regardless.

Thank you for your submission.

Reviewers' comments:

Acceptance letter

Natasha L Pritchard

22 Aug 2024

PONE-D-23-38873R1

PLOS ONE

Dear Dr. malhotra,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Natasha L Pritchard

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Rawdata

    (XLSX)

    pone.0308865.s001.xlsx (99.1KB, xlsx)
    Attachment

    Submitted filename: RESPONSE TO EDITORS & REVIEWERS.docx

    pone.0308865.s002.docx (15.8KB, docx)

    Data Availability Statement

    ll relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES